Molecular Partners
MOLN
15 hedge funds and large institutions have $35.1M invested in Molecular Partners in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
5.32% more ownership
Funds ownership: 0% → 5.32% (+5.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$7.94M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.96M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.67M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$3.47M |
| 5 |
BlackRock
New York
|
+$3.27M |
Top Sellers
MOLN Hedge Fund Activity: Q2 2021 in Review
15 of the 5,766 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q2 2021, worth a combined $35.1M.
Buyers outnumbered sellers: 15 funds opened new MOLN positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Suvretta Capital Management, opening a new position worth an estimated $7.94M.
- 15 institutional investors held Molecular Partners (MOLN) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $35.1M of Molecular Partners stock for Q2 2021.
- 15 funds opened new Molecular Partners positions in Q2 2021 and 0 closed out, a net change of +15 holders.
- The largest Molecular Partners buyer in Q2 2021 was Suvretta Capital Management, an estimated $7.94M added.
Based on aggregated 13F filings for Q2 2021.